- Aug 14, 2018
- 727
- 188
- 63
MK-677 is unusual among the compounds discussed in gym circles: it actually has proper human clinical trials behind it, because it was developed as a drug candidate. It's not growth hormone itself — it's a ghrelin mimetic that signals your pituitary to release more of your own GH. The research shows it reliably raises GH and IGF-1 and adds some lean mass over months; it also shows increased appetite and body weight, worsened blood sugar in trials, and it's precisely those trade-offs that got it set aside as a drug — which is the honest picture anyone researching it should start from.
The flagship study is Nass and colleagues' 2008 trial in the Annals of Internal Medicine: healthy older adults took MK-677 or placebo for two years. The drug group showed significantly increased GH and IGF-1 levels, gained fat-free mass, and stored more water and some fat, while strength did not meaningfully improve despite the extra lean mass — a finding worth sitting with, because scale "lean mass" on a scan includes water and isn't the same as contractile muscle. Appetite increased, especially early. Fasting blood sugar rose and insulin sensitivity fell in the treatment group, and a few participants developed blood-sugar readings in the diabetic range. Other trials and reviews echo the pattern: real hormonal effects, real metabolic costs.
Two more educational points the marketing skips. First, regulatory status: MK-677 is not an approved medication in Canada or the US (development was discontinued), and the World Anti-Doping Agency prohibits it — it's a named growth-hormone secretagogue on the banned list, and athletes have tested positive for it. Second, the sleep claims: ghrelin-receptor drugs do affect sleep architecture in some studies, and users commonly report vivid dreams and deeper sleep — plausible, partially supported, but studied far less rigorously than the metabolic effects.
There's also the purity caveat that applies to every unregulated compound: what's sold as MK-677 in grey-market channels is not subject to pharmaceutical quality control, and independent testing of similar products regularly finds dose inaccuracies and substitutions.
So the evidence-based summary: a genuinely GH-raising drug with documented downsides that stopped its own development — neither the miracle the sellers describe nor an inert sugar pill. Decisions about it should be made with the Annals paper in mind, not just forum logs.
There's a comparison worth drawing with actual growth hormone research, because people often treat the two as interchangeable. Exogenous GH in trials produces its own well-documented issues — fluid retention, joint pain, carpal tunnel symptoms, and the same direction of effect on blood sugar. MK-677's profile rhymes with that list because the end hormone exposure is similar, which undercuts the common claim that a secretagogue is automatically the "gentle" route. Raising a hormone by signalling the pituitary instead of injecting the hormone itself still raises the hormone, and the downstream effects follow the exposure, not the marketing category.
Has anyone here actually read the Nass trial or the diabetes data? Curious whether the blood-sugar findings change how people weigh this one versus other GH-pathway compounds.
The flagship study is Nass and colleagues' 2008 trial in the Annals of Internal Medicine: healthy older adults took MK-677 or placebo for two years. The drug group showed significantly increased GH and IGF-1 levels, gained fat-free mass, and stored more water and some fat, while strength did not meaningfully improve despite the extra lean mass — a finding worth sitting with, because scale "lean mass" on a scan includes water and isn't the same as contractile muscle. Appetite increased, especially early. Fasting blood sugar rose and insulin sensitivity fell in the treatment group, and a few participants developed blood-sugar readings in the diabetic range. Other trials and reviews echo the pattern: real hormonal effects, real metabolic costs.
Two more educational points the marketing skips. First, regulatory status: MK-677 is not an approved medication in Canada or the US (development was discontinued), and the World Anti-Doping Agency prohibits it — it's a named growth-hormone secretagogue on the banned list, and athletes have tested positive for it. Second, the sleep claims: ghrelin-receptor drugs do affect sleep architecture in some studies, and users commonly report vivid dreams and deeper sleep — plausible, partially supported, but studied far less rigorously than the metabolic effects.
There's also the purity caveat that applies to every unregulated compound: what's sold as MK-677 in grey-market channels is not subject to pharmaceutical quality control, and independent testing of similar products regularly finds dose inaccuracies and substitutions.
So the evidence-based summary: a genuinely GH-raising drug with documented downsides that stopped its own development — neither the miracle the sellers describe nor an inert sugar pill. Decisions about it should be made with the Annals paper in mind, not just forum logs.
There's a comparison worth drawing with actual growth hormone research, because people often treat the two as interchangeable. Exogenous GH in trials produces its own well-documented issues — fluid retention, joint pain, carpal tunnel symptoms, and the same direction of effect on blood sugar. MK-677's profile rhymes with that list because the end hormone exposure is similar, which undercuts the common claim that a secretagogue is automatically the "gentle" route. Raising a hormone by signalling the pituitary instead of injecting the hormone itself still raises the hormone, and the downstream effects follow the exposure, not the marketing category.
Has anyone here actually read the Nass trial or the diabetes data? Curious whether the blood-sugar findings change how people weigh this one versus other GH-pathway compounds.